Clinical Trial Update: Evaluation of Safety and Feasibility of OGX-011 in Combination With 2nd-line Chemotherapy in Patients With HRPC [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating OGX-011 in combination with second-line chemotherapy in hormone-refractory prostate cancer has completed and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• OGX-011 (custirsen)

Snippet

Sponsor: Achieve Life Sciences | Conditions: Prostate Cancer | Phase 2 | Status: COMPLETED | Results posted: 2012-08-29